Unique ID issued by UMIN | UMIN000039916 |
---|---|
Receipt number | R000045522 |
Scientific Title | Prospective evaluation of vedolizumab-effects in patients with inflammatory bowel diseases |
Date of disclosure of the study information | 2020/05/11 |
Last modified on | 2020/05/23 13:53:17 |
Prospective evaluation of vedolizumab-effects in patients with inflammatory bowel diseases
VED IBD Cohort Study
Prospective evaluation of vedolizumab-effects in patients with inflammatory bowel diseases
VED IBD Cohort Study
Japan |
ulcerative colitis and Crohn's disease
Medicine in general | Gastroenterology |
Others
NO
Evaluation of vedolizumab-effects in prospective single-center cohort of IBD patients
Efficacy
Persistence of vedolizumab at week 54
Observational
18 | years-old | <= |
Not applicable |
Male and Female
Patients with inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease treated with vedolizumab
1. Patients without informed consent
2. Patients determined to be inappropriate by doctor
50
1st name | Shingo |
Middle name | |
Last name | Kato |
Saitama Medical Center, Saitama Medical University
Department of Gastroenterology and Hepatology
350-8550
1981 Kamoda, Kawagoe City, Saitama 3508550, Japan
049-228-3564
skato@saitama-med.ac.jp
1st name | Shingo |
Middle name | kato |
Last name | Kato |
Saitama Medical Center, Saitama Medical University
Department of Gastroenterology and Hepatology
350-8550
1981 Kamoda, Kawagoe City, Saitama 3508550, Japan
049-228-3564
skato@saitama-med.ac.jp
Saitama Medical Center, Saitama Medical University
Saitama Medical Center, Saitama Medical University
Self funding
IRB of Saitama Medical Center
1981 Kamoda, Kawagoe City, Saitama 3508550, Japan
049-228-3902
smcrinri@saitama-med.ac.jp
NO
2020 | Year | 05 | Month | 11 | Day |
Unpublished
Terminated
2020 | Year | 05 | Month | 07 | Day |
2020 | Year | 05 | Month | 14 | Day |
2020 | Year | 05 | Month | 11 | Day |
2024 | Year | 03 | Month | 31 | Day |
Decision of VED is determined by doctor in clinical practice. All patients determined to be treated by VED were able to be enrolled in this study regardless of their clinical activities or history of treatment after the acquisition of informed consent. Shortening of vedolizumab treatment ever 4 weeks were not permitted in Japan.
The name of this study was determined not to be appropriate by the IRB in Saitama Medical Center and was re-registered as UMIN000040175.
2020 | Year | 03 | Month | 23 | Day |
2020 | Year | 05 | Month | 23 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045522
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |